Haematological Malignancy: Types, Causes, and Treatments

Haematological malignancies are cancers that begin in the blood, bone marrow, or lymphatic system, and they account for a substantial share of cancer diagnoses worldwide. The term covers a broad family of diseases, from fast-moving acute leukemias to slow-growing chronic conditions and solid tumors of the lymph nodes. What unites them is their origin in the cells that normally produce blood or defend the body against infection. The biology, outlook, and treatment of each type differ enough that “blood cancer” is really an umbrella over dozens of distinct diseases, each with its own genetic fingerprint and clinical behavior.

The Main Categories of Blood Cancer

Blood cancers fall into three broad groups based on the cell type involved and where the disease primarily develops. Leukemias arise in the bone marrow and spill into the bloodstream. Lymphomas grow in the lymph nodes or other lymphoid tissue. Myeloma targets plasma cells, a specialized type of white blood cell that normally produces antibodies. Within each group, the picture gets more specific.

Leukemias are split first by speed: acute leukemias progress rapidly and require urgent treatment, while chronic leukemias develop slowly and may be monitored for years before treatment is needed. They are then split by cell lineage. Acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) begin in lymphoid cells, while acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) begin in myeloid cells. The fifth edition of the World Health Organization classification has further refined these categories by incorporating genetic and molecular features alongside traditional microscopy, recognizing that two leukemias that look similar under a microscope can behave very differently depending on their underlying mutations.¹

Lymphomas divide into Hodgkin lymphoma and non-Hodgkin lymphoma. Classic Hodgkin lymphoma is defined by the presence of distinctive large cells called Hodgkin Reed-Sternberg cells, which have a characteristic “owl’s eye” appearance under the microscope. These unusual cells are actually scarce within the tumor; the bulk of the mass is made up of surrounding inflammatory cells. Despite their small numbers, the Reed-Sternberg cells drive the disease.² Interestingly, the actual count or ratio of these cells within the tumor does not appear to predict how well a patient responds to treatment or how long they survive.³ Non-Hodgkin lymphomas are far more diverse, encompassing dozens of subtypes that range from highly aggressive (like Burkitt lymphoma) to very indolent (like follicular lymphoma).

Multiple myeloma develops when plasma cells in the bone marrow multiply uncontrollably. One of its hallmarks is bone destruction. The cancer cells disrupt the normal balance between cells that build bone and cells that break it down, tipping the scales heavily toward breakdown. This leads to painful bone lesions, fractures, and elevated calcium in the blood.⁴

Pre-Malignant Conditions and the Road to Full-Blown Disease

Not every blood disorder that looks worrying under a microscope is already cancer. Myelodysplastic syndromes (MDS) are a group of conditions in which the bone marrow produces abnormal blood cells that do not mature properly. MDS is sometimes called a “pre-leukemia” because it can progress to AML, though many patients live with it for years without that happening. In a large study of nearly 2,000 lower-risk MDS patients, about two-thirds remained in that lower-risk category throughout their disease course. Roughly one in six progressed to a higher-risk form of MDS without developing AML, while about 9% jumped directly from lower-risk MDS to AML.⁵

Research into how MDS transforms into AML has revealed that the change does not follow a simple straight line. At the stem cell level, multiple competing clones of abnormal cells exist simultaneously. Some of those clones may be undetectable during the MDS phase but become dominant when the disease transforms into leukemia. This means the AML that emerges is not always a direct descendant of the most obvious MDS clone; it can spring from a previously hidden subpopulation of stem cells.⁶ Certain gene mutations, including changes in IDH1, IDH2, and NPM1, are more common in patients whose MDS transforms directly to AML, while mutations in genes like ASXL1 and TP53 tend to appear when MDS progresses to a higher-risk form without immediately becoming leukemia.⁵

What Causes Blood Cancers

Most haematological malignancies arise from a combination of genetic vulnerability and environmental triggers, though in many individual cases, no single clear cause can be pinpointed. The causes vary substantially by disease type.

Genetic changes are central. The Philadelphia chromosome is one of the best-understood examples: a swap of genetic material between chromosomes 9 and 22 produces a fusion gene called BCR-ABL1. The protein made by this fusion gene is a permanently switched-on enzyme that drives cells to multiply without the usual controls. This abnormality defines CML and also appears in some cases of ALL.⁷ The fusion protein does not just flip one switch; it activates multiple signaling pathways that collectively push cells toward uncontrolled growth and resistance to normal cell death.¹

Environmental exposures play a documented role in certain blood cancers. Benzene, a chemical found in petroleum products, industrial solvents, and cigarette smoke, is a well-established cause of AML and likely contributes to other blood cancers too. It damages blood-forming stem cells through a combination of genetic damage, chromosomal abnormalities, and disruption of the bone marrow environment.⁸ A population-based study found that benzene exposure roughly doubled the risk of AML and raised the risk of MDS by about 77%. Vinyl chloride exposure carried a similar increase in risk. Exposure to soot, creosote, inks, dyes, and coal dust was associated with a two- to fourfold increase in AML risk specifically.⁹

Viruses account for a meaningful share of lymphomas. Epstein-Barr virus (EBV, the virus behind mononucleosis), human T-lymphotropic virus 1 (HTLV-1), HIV, the herpesvirus that causes Kaposi sarcoma, and hepatitis C virus have all been linked to the development of lymphoma.¹⁰ EBV was the first human cancer-causing virus discovered, and both EBV and HTLV-1 can immortalize lymphocytes in laboratory conditions, meaning they give cells the ability to divide indefinitely.¹¹

Childhood leukemia occupies its own etiological territory. ALL is the most common childhood cancer, and about 80% of pediatric cases arise from precursor B cells. Case-control studies have consistently found an inverse relationship between early infection exposure and ALL risk: children who attend daycare and those with older siblings (and therefore more early exposure to common germs) develop ALL less frequently. There is also evidence that children who later develop leukemia may have a subtle difference in immune function from birth, including lower levels of certain immune-regulating molecules.¹²

The Bone Marrow Microenvironment and Why It Matters

One of the more frustrating aspects of treating blood cancers is that the bone marrow itself can act as a shelter for malignant cells. The bone marrow is not just a factory for blood cells; it is a complex tissue with blood vessels, fat cells, connective tissue, and nerve fibers, all of which communicate with blood-forming stem cells. In leukemia, the cancer cells hijack these support systems.

Leukemia stem cells nestle into the bone marrow niche and receive survival signals from surrounding stromal cells. This crosstalk can make leukemia cells resistant to chemotherapy by providing alternative energy sources, triggering protective signaling pathways, and physically shielding cancer cells from drug exposure.¹³ Fat cells in the marrow, for example, feed leukemia cells fatty acids that sustain their survival and migration. Blood vessel lining cells form direct physical connections with leukemia blasts, and connective tissue stem cells promote the growth and drug resistance of leukemic cells through ramped-up signaling.¹⁴

The cancer cells are not passive recipients of this help. They actively reprogram their surroundings, converting the normal marrow environment into one that favors leukemia growth over healthy blood production. This reprogramming is now recognized as a significant contributor to drug resistance, and targeting the interaction between leukemia stem cells and the marrow niche is a growing area of treatment research.¹⁵

How Blood Cancers Are Diagnosed and Monitored

Diagnosis typically begins with a complete blood count and microscopic examination of blood and bone marrow samples, but modern haematology leans heavily on molecular techniques. Flow cytometry, which identifies cell types by tagging surface proteins with fluorescent markers, remains a workhorse for both initial diagnosis and ongoing monitoring. After treatment, detecting the tiny number of cancer cells that may survive is critical for predicting relapse. This is called measurable residual disease (MRD) testing.

Next-generation sequencing (NGS), which reads the DNA of individual cells to look for cancer-related mutations, is increasingly used alongside flow cytometry. Both methods have comparable sensitivity for detecting leftover disease, but they catch different things. Flow cytometry identifies abnormal protein patterns on cells, while NGS detects genetic mutations. Patients who test negative by both methods have the best outlook. When both are positive, the risk of relapse is highest. Used together, the two techniques provide a more complete picture than either alone.¹⁶ This dual approach is increasingly being adopted to guide decisions about whether to intensify therapy or proceed to transplant.¹⁷

Treatment Approaches

Treatment for haematological malignancies has expanded dramatically beyond traditional chemotherapy, though chemotherapy still forms the backbone for many disease types. The choice of treatment depends on the specific diagnosis, the patient’s age and fitness, and increasingly on the molecular profile of their cancer.

Targeted Small-Molecule Drugs

The poster child for targeted therapy in blood cancer is imatinib, the first tyrosine kinase inhibitor (TKI) designed to block the BCR-ABL1 fusion protein in CML. This drug transformed CML from a near-certain death sentence into a manageable chronic condition for most patients. Several newer TKIs have followed, offering alternatives for patients who do not respond to or cannot tolerate the first drug. However, long-term use of TKIs brings its own challenges. About 10% of patients cannot tolerate their initial TKI, and side effects accumulate over years of continuous use, particularly cardiovascular and pulmonary complications with second-generation drugs. For some long-term responders, the side effects of treatment have a greater impact on quality of life than the disease itself.¹⁸

Newer targeted agents are being developed for specific genetic subtypes. Menin inhibitors, for instance, target a protein complex that is essential for leukemia cells carrying certain rearrangements of the KMT2A gene or mutations in NPM1. These leukemia cells depend on the menin-KMT2A interaction to maintain their cancerous self-renewal program, making it a precise vulnerability.¹⁹ In pediatric ALL, a number of small molecules targeting specific molecular pathways are in early-phase clinical trials, with the goal of building molecularly guided treatment strategies that go beyond one-size-fits-all chemotherapy.²⁰

CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy engineers a patient’s own immune cells to recognize and kill cancer. The most widely used version targets a protein called CD19, found on the surface of most B-cell cancers. This approach has reshaped treatment for patients with B-cell non-Hodgkin lymphoma and B-cell ALL who have relapsed after or failed to respond to standard therapies.²¹ For multiple myeloma, CAR T-cell therapy targeting a different protein, BCMA (B-cell maturation antigen), has shown significant results in clinical trials, offering a new option for patients whose disease has resisted multiple prior treatments.²²

The technology is not without limitations. A substantial number of patients relapse after CAR T-cell therapy, sometimes because the cancer cells lose the protein the CAR T cells were designed to target, and sometimes because the engineered T cells lose their potency over time.²¹ The treatment can also cause serious short-term side effects, including cytokine release syndrome, a potentially dangerous immune overreaction.

Bispecific T-Cell Engagers

Bispecific T-cell engagers (BiTEs) are a different approach to harnessing the immune system. These are small engineered proteins that physically link a patient’s T cells to cancer cells. One end grabs a T cell (usually via the CD3 receptor), and the other end latches onto a protein on the tumor cell’s surface. This forced proximity activates the T cell and triggers it to kill the cancer cell directly.²³ Blinatumomab, for example, bridges CD19 on B-cell cancers with CD3 on T cells, forming a tight immune synapse that leads to targeted killing through the release of cell-destroying enzymes.²⁴ Because BiTEs are small molecules without the bulky constant region of traditional antibodies, they can form tighter connections between the two cells than a conventional antibody could.

Stem Cell Transplantation

Allogeneic stem cell transplant, in which a patient receives blood-forming stem cells from a donor, remains one of the most powerful treatments for high-risk or relapsed blood cancers. Much of its effectiveness comes from the graft-versus-leukemia (GvL) effect: the donor’s immune cells recognize and attack residual cancer cells in the recipient’s body. This immune attack can be driven by donor T cells, natural killer cells, and even dendritic cells of leukemic origin that activate the donor immune response.²⁵ Among the immune cells involved, CD4+ T cells play a central coordinating role, and how immunogenic the leukemia itself is helps determine how strong the GvL response will be.²⁶

The flip side of this immune power is graft-versus-host disease, where the donor immune cells also attack the patient’s healthy tissues. Managing that balance between killing cancer and sparing normal organs remains one of the central challenges of transplant medicine.

Living with and After Blood Cancer

Survival rates for many haematological malignancies have improved dramatically, which means a growing population of people lives with the long-term consequences of treatment. A national survey of over 1,100 people affected by AML found that 87% reported severe short-term treatment effects and a third reported severe long-term effects. Hair loss and fatigue topped both lists. Only about 11% experienced no severe effects at all.²⁷

For childhood leukemia survivors, the stakes of long-term follow-up are especially high. Large cohort studies show that about a fifth of ALL survivors and most AML survivors have at least one chronic health condition within two to two and a half decades of diagnosis. These can include second cancers, heart damage from chemotherapy, hormonal disruptions, bone problems, fertility impairment, and neurological effects. Some of these conditions are life-threatening and contribute to premature death in survivors who were cured of their original cancer.²⁸

Global Disparities in Outcomes

Where you live matters enormously for blood cancer outcomes. Globally, the ratio of mortality to incidence for haematological malignancies varies widely by region and is strongly tied to a country’s economic development. Countries with lower human development, lower national income, and less access to essential cancer medicines consistently see higher death rates relative to diagnosis rates.²⁹ Older patients fare worse everywhere, but the gap between wealthy and poor countries is especially stark.

Childhood ALL illustrates the problem clearly. While cure rates have climbed steadily in high-income countries, applying those same intensive treatment protocols in low- and middle-income settings without the infrastructure for safe drug delivery and supportive care can do more harm than good, leading to treatment-related deaths and families abandoning therapy that outweigh any cancer-fighting benefit.³⁰ Indigenous populations face additional disadvantages. A global systematic review found that Indigenous peoples with blood cancer consistently experience poorer survival than non-Indigenous groups, a pattern documented primarily in high-income countries, with very little data available from the rest of the world.³¹

Unusual Clinical Presentations

Blood cancers do not always announce themselves with the expected fatigue, bruising, and swollen lymph nodes. In rare cases, the first sign can be something seemingly unrelated. Ischemic stroke, for example, has been documented as the initial presentation in patients who turned out to have AML or MDS. The mechanisms behind this are complex and can include extremely high white blood cell counts clogging small blood vessels, inflammatory molecules disrupting normal blood clotting, and direct interactions between leukemia cells and the cells lining blood vessels.³² These atypical presentations are rare enough that they can delay diagnosis, particularly when the patient has no prior blood count abnormalities on file. They serve as a reminder that blood cancers can affect nearly any organ system, not just the blood and bone marrow.